In vitro partition of irinotecan (CPT-11) in human volunteer blood: the influence of concentration, gender and smoking

被引:10
作者
Dumez, H
Guetens, G
De Boeck, G
Highley, MS
de Bruijn, EA
van Oosterom, AT
Maes, RAA
机构
[1] UZ Gasthuisberg, Dept Clin Oncol, Expt Oncol Lab, B-3000 Louvain, Belgium
[2] Univ Utrecht, Fac Pharmaceut Sci, Utrecht, Netherlands
关键词
irinotecan; partition; red blood cell; smoking;
D O I
10.1097/01.cad.0000175584.86198.ac
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We have performed in vitro incubations of blood from male and female volunteers, smokers and non-smokers, with irinotecan at a gradient of different concentrations in order to investigate changes of partition between red blood cells (RBCs), total plasma and the free fraction. Since irinotecan (CPT-11) is not metabolized in vitro, there is no data available on its active metabolite SN-38. After extraction and sample pre-treatment, a validated high-performance liquid chromatography method followed by fluorescence detection was used to determine the concentration of the drug in the different blood constituents. The partition ratio [the concentration in the erythrocytes divided by the concentration in plasma (E/P)] was calculated. The partition ratio of CPT-11 varied from 0.7 to 2.8, reflecting its relatively high affinity for the erythrocyte, probably because of its only moderate plasma protein binding (65%). The partition ratios increased significantly with higher whole-blood concentrations, favoring uptake in the erythrocytes when plasma protein binding is saturated. No gender difference was detected, but we found relatively more CPT-11 in the erythrocytes of non-smokers compared to smokers. The incorporation of drugs into the RBC pool may be important for transportation to tumor tissue and efficacy. Smoking can have a significant influence on drug partition in the blood.
引用
收藏
页码:893 / 895
页数:3
相关论文
共 14 条
[1]   Clinical pharmacokinetics of irinotecan [J].
Chabot, GG .
CLINICAL PHARMACOKINETICS, 1997, 33 (04) :245-259
[2]   POPULATION PHARMACOKINETICS AND PHARMACODYNAMICS OF IRINOTECAN (CPT-11) AND ACTIVE METABOLITE SN-38 DURING PHASE-I TRIALS [J].
CHABOT, GG ;
ABIGERGES, D ;
CATIMEL, G ;
CULINE, S ;
DEFORNI, R ;
EXTRA, JM ;
MAHJOUBI, H ;
HERAIT, P ;
ARMAND, JP ;
BUGAT, R ;
CLAVEL, M ;
MARTY, ME .
ANNALS OF ONCOLOGY, 1995, 6 (02) :141-151
[3]   Determination of irinotecan (CPT-11) and SN-38 in human whole blood and red blood cells by liquid chromatography with fluorescence detection [J].
de Jong, FA ;
Mathijssen, RHJ ;
de Bruijn, P ;
Loos, WJ ;
Verweij, J ;
Sparreboom, A .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2003, 795 (02) :383-388
[4]   DESCRIPTION OF AN INSTRUMENT FOR SEPARATION OF RED-CELLS FROM PLASMA AND MEASUREMENT OF RED-CELL VOLUME [J].
DRIESSEN, O ;
HIGHLEY, MS ;
HARPER, PG ;
MAES, RAA ;
DEBRUIJN, EA .
CLINICAL BIOCHEMISTRY, 1994, 27 (03) :195-196
[5]   In vitro partition of docetaxel and gemcitabine in human volunteer blood: the influence of concentration and gender [J].
Dumez, H ;
Guetens, G ;
De Boeck, G ;
Highley, MS ;
de Bruijn, EA ;
van Oosterom, AT ;
Maes, RAA .
ANTI-CANCER DRUGS, 2005, 16 (08) :885-891
[6]   Human red blood cells: Rheological aspects, uptake, and release of cytotoxic drugs [J].
Dumez, H ;
Reinhart, WH ;
Guetens, G ;
de Bruijn, EA .
CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES, 2004, 41 (02) :159-188
[7]  
DUMEZ H, 2005, IN PRESS ANN ONCOL
[8]  
Hinderling PH, 1997, PHARMACOL REV, V49, P279
[10]  
KURATA D, 1974, CLIN PHARMACOL THER, V16, P355